Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.
Recursion Pharmaceuticals shares were 11% higher, at $3.90, after the company reported fourth-quarter revenue that was higher than last year, and a loss that was narrower than last year's.
A developer-targeting campaign leveraged malicious Next.js repositories to trigger a covert RCE-to-C2 chain through standard ...
Windows 11 feeling bloated? Sophia Script lets you reshape the OS from the inside out. Here's how it works.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results